Predictors of early discharge after transcatheter aortic valve implantation: insight from the CoreValve ClinicalService.
Journal
Journal of cardiovascular medicine (Hagerstown, Md.)
ISSN: 1558-2035
Titre abrégé: J Cardiovasc Med (Hagerstown)
Pays: United States
ID NLM: 101259752
Informations de publication
Date de publication:
01 07 2022
01 07 2022
Historique:
entrez:
28
6
2022
pubmed:
29
6
2022
medline:
1
7
2022
Statut:
ppublish
Résumé
The aim of this study was to minimize the procedure, and reduce the length of hospital stay (LoS) is the future objective for transcatheter aortic valve replacement (TAVI).Aims of the study are to identify procedural and electrocardiographical predictors of fast-track discharge in patients who underwent TAVI. Patients treated with TAVI included in the One Hospital ClinicalService project were categorized according to the LoS. 'Fast-Track' population, with a postprocedural LoS less than or equal to 3 days, was compared with the 'Slow-Track' population with a postprocedural LoS greater than 3 days. One thousand five hundred and one patients were collected. Despite single baseline characteristics being almost similar between the two groups, Slow-Track group showed a higher surgical risk (P < 0.001). Patients in the Slow-Track group were more frequently treated with general anaesthesia (P = 0.002) and less frequently predilated (P < 0.001) and received a lower amount of contrast media. No difference between Slow-Track and Fast-Track patients was observed at 30 days in death and in cardiovascular rehospitalization.In the multivariable analysis, STS score of at least 4% [odds ratio (OR): 1.64; P = 0.01], general anaesthesia (OR: 2.80; P = 0.03), predilation (OR: 0.45; P < 001), NYHA 3-4 at baseline (OR: 1.65; P = 0.01), AVB I/LBBB/RBBB onset (OR: 2.41; P < 0.001) and in-hospital new PM (OR: 2.63; P < 0.001) were independently associated with a higher probability of Slow-Track. Fast-Track patients were safely discharged home showing no difference in clinical outcomes after discharge up to 30 days compared with the Slow-Track group. The STS score, general anaesthesia, NYHA 3--4 at baseline, in-hospital onset of conduction disturbances and new PM implantation after TAVI turned out to be predictors of Slow-Track.
Identifiants
pubmed: 35763766
doi: 10.2459/JCM.0000000000001318
pii: 01244665-202207000-00006
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
454-462Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2022 Italian Federation of Cardiology - I.F.C. All rights reserved.
Références
Geisler BP, Jørgensen TH, Thyregod HGH, et al. Cost-effectiveness of transcatheter versus surgical aortic valve replacement in patients at lower surgical risk: results from the NOTION trial. EuroIntervention 2019; 15:e959–e967.
Barbanti M, van Mourik MS, Spence MS, et al. Optimising patient discharge management after transfemoral transcatheter aortic valve implantation: the multicentre European FAST-TAVI trial. EuroIntervention 2019; 15:147–154.
Wood DA, Lauck SB, Cairns JA, et al. The Vancouver 3 M (Multidisciplinary, Multimodality, But Minimalist) clinical pathway facilitates safe next-day discharge home at low-, medium-, and high-volume transfemoral transcatheter aortic valve replacement centers: the 3 M TAVR study. JACC Cardiovasc Interv 2019; 12:459–469.
Costa G, Barbanti M, Picci A, et al. Predictors and safety of next-day discharge in patients undergoing transfemoral transcatheter aortic valve implantation. EuroIntervention 2020; 16:e494–e501.
Saia F, Palmerini T, Marcelli C, et al. Routine minimalist transcatheter aortic valve implantation with local anesthesia only. J Cardiovasc Med (Hagerstown, Md) 2020; 21:805–811.
Ussia GP, Barbanti M, Petronio AS, et al. Transcatheter aortic valve implantation: 3-year outcomes of self-expanding CoreValve prosthesis. Eur Heart J 2012; 33:969–976.
Kappetein AP, Head SJ, Généreux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol 2012; 60:1438–1454.
Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2017; 38:2739–2791.
Thiele H, Kurz T, Feistritzer HJ, et al. General versus local anesthesia with conscious sedation in transcatheter aortic valve implantation: the Randomized SOLVE-TAVI Trial. Circulation 2020; 142:1437–1447.
Harjai KJ, Bules T, Berger A, et al. Efficiency, safety, and quality of life after transcatheter aortic valve implantation performed with moderate sedation versus general anesthesia. Am J Cardiol 2020; 125:1088–1095.
Petronio AS, Giannini C, De Carlo M, et al. Anaesthetic management of transcatheter aortic valve implantation: results from the Italian CoreValve registry. EuroIntervention 2016; 12:381–388.
Villablanca PA, Mohananey D, Nikolic K, et al. Comparison of local versus general anesthesia in patients undergoing transcatheter aortic valve replacement: a meta-analysis. Catheter Cardiovasc Interv 2018; 91:330–342.
van der Wulp K, van Wely M, van Heijningen L, et al. Delirium after transcatheter aortic valve implantation under general anesthesia: incidence, predictors, and relation to long-term survival. J Am Geriatr Soc 2019; 67:2325–2330.
Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med 2019; 380:1695–1705.
Asch FM, Vannan MA, Singh S, et al. Hemodynamic and echocardiographic comparison of the Lotus and CoreValve Transcatheter aortic valves in patients with high and extreme surgical risk: an analysis from the REPRISE III Randomized Controlled Trial. Circulation 2018; 137:2557–2567.
Jilaihawi H, Zhao Z, Du R, et al. Minimizing permanent pacemaker following repositionable self-expanding transcatheter aortic valve replacement. XXXX 2019.
Rodés-Cabau J. Optimizing valve implantation depth to win the battle against conduction disturbances post-TAVR. JACC Cardiovasc Interv 2019; 1808–1810.
Mangieri A, Lanzillo G, Bertoldi L, et al. Predictors of advanced conduction disturbances requiring a late (≥48 H) permanent pacemaker following transcatheter aortic valve replacement. JACC Cardiovasc Interv 2018; 11:1519–1526.
Maeno Y, Abramowitz Y, Kawamori H, et al. A highly predictive risk model for pacemaker implantation after TAVR. JACC Cardiovasc Imaging 2017; 10:1139–1147.
Taniguchi T, Shirai S, Ando K, et al. Impact of New York Heart Association functional class on outcomes after transcatheter aortic valve implantation. Cardiovasc Revasc Med 2021.
Jhand A, Apala DR, Dhawan R, et al. Meta-analysis comparing transradial versus transfemoral secondary access in transcatheter aortic valve implantation. Am J Cardiol 2020; 131:74–81.
Braghiroli J, Kapoor K, Thielhelm TP, Ferreira T, Cohen MG. Transcatheter aortic valve replacement in low risk patients: a review of PARTNER 3 and Evolut low risk trials. Cardiovasc Diagn Ther 2020; 10:59–71.
Reardon MJ, Van Mieghem NM, Popma JJ, et al. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med 2017; 377:197–198.
Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 2016; 374:1609–1620.
Elbaz-Greener G, Zivkovic N, Arbel Y, Radhakrishnan S, Fremes SE, Wijeysundera HC. Use of two-dimensional ultrasonographically guided access to reduce access-related complications for transcatheter aortic valve replacement. Can J Cardiol 2017; 33:918–924.
Faurie B, Souteyrand G, Staat P, et al. Left ventricular rapid pacing via the valve delivery guidewire in transcatheter aortic valve replacement. JACC Cardiovasc Interv 2019; 12:2449–2459.
Burzotta F, Aurigemma C, Romagonli E, et al. A less-invasive totally-endovascular (LITE) technique for trans-femoral transcatheter aortic valve replacement. Catheter Cardiovasc Interv 2020; 96:
Lauck SB, Wood DA, Baumbusch J, et al. Vancouver transcatheter aortic valve replacement clinical pathway: minimalist approach, standardized care, and discharge criteria to reduce length of stay. Circ Cardiovasc Qual Outcomes 2016; 9:312–321.
Durand E, Eltchaninoff H, Canville A, et al. Feasibility and safety of early discharge after transfemoral transcatheter aortic valve implantation with the Edwards SAPIEN-XT prosthesis. Am J Cardiol 2015; 115:1116–1122.
Barbanti M, Capranzano P, Ohno Y, et al. Early discharge after transfemoral transcatheter aortic valve implantation. Heart 2015; 101:1485–1490.